Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
20
CRIS Quote, Financials, Valuation and Earnings
Last price:
$1.77
Seasonality move
:
-5.84%
Day range:
$1.83 - $1.91
52-week range:
$1.02 - $8.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.15x
P/B ratio:
9.96x
Volume:
77.9K
Avg. volume:
152.6K
1-year change:
-72.25%
Market cap:
$19.3M
Revenue:
$10.9M
EPS (TTM):
-$6.23
Analysts' Opinion
-
Consensus RatingCuris has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.33, Curis has an estimated upside of 787.68% from its current price of $1.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $1.84.
Fair Value
-
According to the consensus of 3 analysts, Curis has 787.68% upside to fair value with a price target of $16.33 per share.
CRIS vs. S&P 500
-
Over the past 5 trading days, Curis has underperformed the S&P 500 by -5.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Curis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Curis has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Curis reported revenues of $2.4M.
Earnings Growth
-
Curis has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Curis reported earnings per share of -$1.25.
Enterprise value:
-1M
EV / Invested capital:
--
Price / LTM sales:
1.15x
EV / EBIT:
--
EV / Revenue:
-0.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$11.1M
Return On Assets:
-89.45%
Net Income Margin (TTM):
-376.09%
Return On Equity:
-461.34%
Return On Invested Capital:
-461.34%
Operating Margin:
-426.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $10.4M | $9.8M | $11.2M | $2.1M | $2.4M | |
| Gross Profit | $10.2M | $9.6M | $11.1M | $2M | $2.4M | |
| Operating Income | -$49.5M | -$49.2M | -$42.2M | -$12.5M | -$10.2M | |
| EBITDA | -$48M | -$46M | -$40.3M | -$12.4M | -$10.1M | |
| Diluted EPS | -$11.02 | -$8.68 | -$6.23 | -$2.05 | -$1.25 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $161.9M | $126.1M | $78M | $46.1M | $24.8M | |
| Total Assets | $190.6M | $140.7M | $94.5M | $62M | $39.3M | |
| Current Liabilities | $7M | $9.7M | $8.1M | $11.3M | $20.1M | |
| Total Liabilities | $68.7M | $64.8M | $58M | $52.6M | $45.9M | |
| Total Equity | $121.9M | $76M | $36.6M | $9.5M | -$6.6M | |
| Total Debt | $891K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.7M | -$39.5M | -$33.6M | -$13.2M | -$7.3M | |
| Cash From Investing | $62.3M | $30.5M | $10.5M | $18.9M | -- | |
| Cash From Financing | $509K | $7.2M | $13.4M | -$2.4M | $7.5M | |
| Free Cash Flow | -$49.7M | -$39.5M | -$33.6M | -$13.2M | -$7.3M | |
CRIS
Sector
Market Cap
$19.3M
$35.2M
Price % of 52-Week High
22.2%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
-100.24%
-1.01%
1-Year Price Total Return
-72.25%
-36.85%
Beta (5-Year)
3.605
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.85
200-day SMA
Sell
Level
$3.10
Bollinger Bands (100)
Sell
Level
1.63 - 2.69
Chaikin Money Flow
Sell
Level
-682.1K
20-day SMA
Sell
Level
$2.00
Relative Strength Index (RSI14)
Sell
Level
42.05
ADX Line
Sell
Level
18.2
Williams %R
Neutral
Level
-65.387
50-day SMA
Sell
Level
$2.14
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-509.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-44.6754)
Sell
CA Score
(Annual)
Level (-5.4128)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.1071)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Stock Forecast FAQ
In the current month, CRIS has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRIS average analyst price target in the past 3 months is $16.33.
-
Where Will Curis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Curis share price will rise to $16.33 per share over the next 12 months.
-
What Do Analysts Say About Curis?
Analysts are divided on their view about Curis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Curis is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Curis's Price Target?
The price target for Curis over the next 1-year time period is forecast to be $16.33 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRIS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Curis is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRIS?
You can purchase shares of Curis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Curis shares.
-
What Is The Curis Share Price Today?
Curis was last trading at $1.77 per share. This represents the most recent stock quote for Curis. Yesterday, Curis closed at $1.84 per share.
-
How To Buy Curis Stock Online?
In order to purchase Curis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
80
SOC alert for Jul 18
Sable Offshore [SOC] is up 11.86% over the past day.
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 5.56% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.31% over the past day.
